Antimicrobial activities of sitafloxacin and comparators against the clinical isolates of less common nonfermenting Gram-negative bacteria

• Main Authors: Guo, Y. (Author), Hu, F. (Author), Shen, S. (Author), Wang, L. (Author), Wu, S. (Author), Yang, F. (Author), Yang, Y. (Author), Zhou, X. (Author)
• Format: Article
• Language: English
• Published: Elsevier Ltd 2022
• Subjects: Antimicrobial susceptibility testing; Minimum inhibitory concentration; Nonfermenting Gram-negative bacteria; Sitafloxacin
• Online Access: View Fulltext in Publisher
• ISBN: 22137165 (ISSN)
• DOI: 10.1016/j.jgar.2022.06.003

Objectives: To evaluate in vitro activities of sitafloxacin and comparators against the clinical isolates of less common nonfermenting Gram-negative bacteria (NFGNB). Methods: The isolates of less common NFGNB were collected during a long period spanning five years from 2016 to 2020 in Huashan Hospital, Fudan University in Shanghai. A broth microdilution method was used to determine the minimum inhibitory concentrations (MICs) of sitafloxacin and comparators. Results: In terms of MIC50/90 values, sitafloxacin was highly active against Stenotrophomonas maltophilia (0.25/1 mg/L), Burkholderia cepacia complex (0.25/2 mg/L), Achromobacter xylosoxidans (0.25/1 mg/L), and Chryseobacterium gleum (1/2 mg/L), but less active for Elizabethkingia (1/8 mg/L) and Chryseobacterium indologenes (16/32 mg/L). Sitafloxacin was more active than other fluoroquinolones against these NFGNB except Chryseobacterium. Conclusion: The results are helpful for clinicians to be aware of the role of sitafloxacin in managing the infections caused by these NFGNB. © 2022 The Authors